Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: J Pathol. 2015 Oct 19;238(1):74–84. doi: 10.1002/path.4637

Figure 6. Pretreatment with anti-CD18 antibody does not impair bacterial defense.

Figure 6

C57BL/6 mice (n=8 per group) were treated intranasally (A) or intravenously (B) with 50 µg/mouse or 30 µg/mouse respectively of control or anti-CD18 antibody 30 min prior to intranasal infection with ~9000 CFUs of K. pneumoniae. To determine success of the pretreatment, residual CD18 expression was assessed on alveolar macrophages (A) and granulocytes (B). Bacterial loads in lung, blood and spleen were determined 24 h after infection. Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile, and largest observation. Comparisons using the Mann-Whitney test. * p < 0.05.